Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PURETHAL Mites SCIT in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis
NCT06920771Phase 3Completed
- Sponsor
- HAL Allergy Group
- Start
- Sep 2024
- Primary completion
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes, Therapeutic Vaccines
- Countries
- 5
01
Overview
A Phase 3 trial of Purethal in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC), sponsored by HAL Allergy Group. Started Sep 2024; status: completed.
02
Drugs
Purethal
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT06920771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06920771.